Navigation Links
The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies
Date:7/31/2014

>

The company’s patented method for controlling adult stem cells to multiply without losing their stem cell properties has applications for many different types of adult stem cells. ASCTC’s approved patents demonstrate the application of the method for production of human liver stem cells, hair follicle stem cells, and human pancreatic stem cells; but the technology has general application to adult stem cells found in many other types of organs and tissues.

In addition to the main focus on adult stem cell technologies, ASCTC’s most recently issued patent applies its cell multiplication methods to produce induced pluripotent stem cells (iPSCs) without transferring exogenous genes. This gene-free single agent method should offer significant value to the many mushrooming companies that supply iPSCs and iPSC production reagents.

As a small start-up, ASCTC is employing a social media marketing strategy. In the past week, the company has launched patent licensing ads on LinkedIn, Vocus, and Facebook, as well increased its advertising references within its recently established Twitter presence.

“It would be a shame for these technologies to lie dormant, just because our hands are full with other projects at the moment.” James Sherley, director of ASCTC, relates that the company’s two main business efforts require only a fraction of its available intellectual property. ASCTC is currently focused on bringing laboratory-scale production of human liver stem cells to manufacturing scales and developing a computer simulation assay for preclinical
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development
2. Worlds Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program
3. Study: RSV often milder than flu in older adults
4. FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients
5. First animal model of adult-onset SMA sheds light on disease progression & treatment
6. Vet-Stem, Inc. Founder and CEO, Robert Harman, DVM, Invited to Speak at the Adult Stem Cell Therapy and Regenerative Medicine Conference
7. Visiting Nurse Association of Northern New Jersey Announces Gardening Program at Friendship House Adult Day Care
8. Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced
9. Are Eczema and Acne Related? Probiotic Action Sheds Light on New Ways to Treat Adult Eczema
10. What Causes Acne? Adult Acne Treatment, Probiotic Action, Shares Insight on New Culprits Causing Breakouts
11. Adult Acne Treatment Explains a New Upcoming Study that may Change the Acne Treatment Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 2015 , ... Costello served as Lead Levee Design Engineering Manager for a ... Texas area from future storm surge flooding, such as occurred in Hurricane Ike in ... alternatives for providing protection, Costello also balanced socio-economic and environmental needs and ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... is making good progress in evaluating the full range of capabilities of its ... Adult tissue stem cells perform the day-to-day renewal and repair of normal tissues ...
(Date:7/28/2015)... A n ew UK company ... commercialising innovative medicines to transform patient quality of life and ... team; blue chip investor ... Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that it ... blue chip institutional investors and simultaneously acquired a portfolio of ...
(Date:7/28/2015)... (PRWEB) , ... July 29, 2015 , ... The new Xsample 530 sample changer ... handles a wide range of liquid viscosities – from less than 12,000 mPas (internal air) ... mL vials. , What immediately catches the eye about Xsample 530 is its removable ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... Neb. and HOUSTON, Dec. 2 Transgenomic,Inc. ... Products, Inc. (OTC,Bulletin Board: PWRM) today announced ... to acquire exclusive rights for Power3 Medical,s ... for Alzheimer,s,and Parkinson,s disease. Transgenomic plans ...
... EMERYVILLE, Calif., Dec. 2 Bionovo, Inc.,(Nasdaq: BNVI ), ... effective drugs in the areas of women,s health and,cancer, announced that ... of the Company at the 20th Annual Piper Jaffray Health,Care Conference ... will be held at,the New York Palace Hotel in New York ...
... Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) ... quarter and fiscal year 2008 on December 11, 2008, at approximately ... p.m. ET Martek will conduct a conference call to discuss these ... call live via webcast by visiting Martek,s web site at ...
Cached Biology Technology:Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4Bionovo to Present at the Piper Jaffray Healthcare Conference 2
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... the Department of Human Evolution, Max Planck Institute for ... St. Louis, has extracted and sequenced protein from a ... years old. , This is the oldest fossil human ... week of March 7-11 in the online early edition ...
... large, randomized clinical trial for patients with previously ... has spread from the breast to other parts ... received bevacizumab (Avastin? in combination with standard chemotherapy ... progressed than patients who received the same chemotherapy ...
... of Texas M. D. Anderson Cancer Center have developed a ... the widely used chemotherapy drug Taxol are effectively killing tumor ... make it possible to accurately assess whether patients are responding ... of beginning therapy. , In two different studies being ...
Cached Biology News:Oldest fossil human protein ever sequenced 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 3Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol 2Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol 3
... Source: Tritirachium album Description: Proteinase ... used in a wide range of applications purified ... bonds mainly following the carboxyl group of N-substituted ... and is classified as a serine protease. Proteinase ...
... The H2OBIT is a fully licensed, high ... simultaneous processing of up to 24 microplates. This ... 384-well plates. ,A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
... Dideoxycytidine Dideoxycytidine is a cytidine analog that ... retroviral activity. Immunogen: Chemical / ... The specificity of the ddC antiserum was ... of ddC to moles of ddC analog at ...
... series of Class II Biological Safety ... certification to the world's highest safety ... the cabinets cannot be adjusted out ... low noise and arm rest ensure ...
Biology Products: